With 0.18 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.28 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $10.52 whereas the lowest price it dropped to was $9.93. The 52-week range on MBX shows that it touched its highest point at $27.50 and its lowest point at $4.81 during that stretch. It currently has a 1-year price target of $37.40.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MBX was down-trending over the past week, with a drop of -6.03%, but this was down by -15.39% over a month. Three-month performance surged to 22.38% while six-month performance fell -45.72%. A look at the trailing 12-month EPS for MBX yields -2.20 with Next year EPS estimates of -2.68. For the next quarter, that number is -0.75. This implies an EPS growth rate of 52.89% for this year and 2.26% for next year.
Float and Shares Shorts:
At present, 33.42 million MBX shares are outstanding with a float of 14.84 million shares on hand for trading. On 2025-05-30, short shares totaled 4.75 million, which was 1420.0 higher than short shares on 1745971200. In addition to Mr. Peter Kent Hawryluk MBA as the firm’s CEO, President & Director, Mr. Richard B. Bartram CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 1.0684301 of MBX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, MBX reported revenue of $0.0 and operating income of -$26529000.0. The EBITDA in the recently reported quarter was -$26452000.0 and diluted EPS was -$0.71.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With MBX analysts setting a high price target of 44.0 and a low target of 30.0, the average target price over the next 12 months is 37.4. Based on these targets, MBX could surge 328.02% to reach the target high and rise by 191.83% to reach the target low. Reaching the average price target will result in a growth of 263.81% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$5.27693 being high and -$23.87225 being low. For MBX, this leads to a yearly average estimate of -$11.51884.
